ARTICLE | Clinical News
Second generation carbidopa/levodopa: Phase II data
October 5, 2009 7:00 AM UTC
Top-line data from an active-controlled, U.S. Phase II trial in 27 patients showed that IPX066 met the primary endpoint of significantly reducing "off" time during waking hours by 2 hours vs. Sinemet ...